Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03053063 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03053063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03053063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
January 30, 2017
Completion date
May 6, 2019
Enrollment
883 (actual)
Sites
283

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis